T-47D-luc Orthotopic Mouse Model Service for Breast Cancer

The T-47D-luc orthotopic mouse model integrates the hormone-responsive luminal A biology of the parental T-47D line with firefly luciferase reporter technology, enabling longitudinal, non-invasive quantification of tumor burden and therapeutic response kinetics within the native mammary microenvironment. Alfa Cytology builds and manages this orthotopic xenograft platform with authenticated luciferase-expressing cell stocks, standardized estrogen supplementation regimens, and integrated IVIS bioluminescence imaging infrastructure, delivering quantitative in vivo datasets that capture tumor growth dynamics, treatment-induced regression, and recurrence patterns with temporal resolution unattainable through caliper-based monitoring alone.

Overview of T-47D-luc Orthotopic Mouse Model for Breast Cancer

The T-47D-luc cell line represents a genetically engineered derivative of the canonical T-47D human breast adenocarcinoma line, stably transduced with firefly luciferase (Photinus pyralis luc2) via lentiviral or electroporation-based delivery systems under constitutive CMV promoter control, with hygromycin or puromycin selection ensuring sustained reporter expression across passages. Retaining the parental line's luminal A molecular identity—characterized by robust estrogen receptor alpha (ER^α) and progesterone receptor (PR) co-expression, absence of HER2/neu amplification, and TP53/PIK3CA mutational background—the luciferase-modified variant additionally emits quantifiable bioluminescent signals upon D-luciferin substrate administration. This optical reporting capability transforms the T-47D orthotopic model from a static endpoint system into a dynamic, real-time monitoring platform, where tumor establishment, exponential growth, treatment-induced stasis or regression, and potential regrowth can be visualized and quantified serially in the same animal cohort without invasive intervention.

Fig 1. DHW-208 suppressed the PI3K/AKT/mTOR-signaling pathway in T47D and MDA-MB-231 cells. (Wang, Shu, et al., 2020)

Orthotopic engraftment of T-47D-luc cells into the murine mammary fat pad reconstructs the steroid hormone milieu and stromal architecture of clinical luminal A disease, with the critical requirement of exogenous estrogen supplementation—typically delivered as subcutaneous 17β-estradiol valerate injections (1 µg per animal, twice weekly) or slow-release pellets—to sustain tumor viability. Tumors generally become bioluminescent-positive within 10–14 days post-implantation, with signal intensity correlating strongly with caliper-derived tumor volume. The model's moderate growth kinetics (reaching 800–1,200 mm³ over 6–8 weeks) provide an extended therapeutic window ideal for evaluating chronic endocrine interventions, sequential treatment strategies, and resistance emergence. The combination of hormone-dependent tumor biology and bioluminescence tracking renders this model particularly powerful for dissecting the temporal pharmacodynamics of selective estrogen receptor degraders, CDK4/6 inhibitors, and PI3K pathway antagonists in the preclinical setting.

Cell Line Information: T-47D-luc

The T-47D-luc cell line merges the well-established luminal A phenotype of the parental T-47D line with a stably integrated firefly luciferase reporter cassette, enabling quantitative optical readouts of tumor burden and treatment response. The table below consolidates its essential biological, genetic, reporter, and culture parameters:

Our Services

Alfa Cytology delivers a turnkey T-47D-luc orthotopic model service that spans luciferase-expressing cell line banking, estrogen preconditioning, surgical mammary fat pad implantation, serial bioluminescence imaging, therapeutic dosing, and comprehensive molecular endpoint analysis. Our platform is engineered to capture the full temporal arc of tumor response—from initial signal detection through treatment-induced regression and potential recurrence—providing your team with quantitative, mechanism-informed datasets that inform compound prioritization and resistance strategy development.

Workflow of T-47D-luc Orthotopic Mouse Model Construction

Establishment of the T-47D-luc orthotopic model requires coordinated execution of hormone priming, sterile surgical technique, and bioluminescence imaging calibration to achieve consistent engraftment and reproducible optical signal kinetics. The protocol proceeds through the following stages:

1. Cell Expansion and Luciferase Validation: T-47D-luc cells are propagated under antibiotic selection to maintain luciferase expression, authenticated via STR profiling, and confirmed mycoplasma-negative. Luciferase activity is quantified in vitro using a D-luciferin luminometric assay to verify reporter functionality prior to in vivo implantation. Cells are harvested during logarithmic growth, counted, and resuspended in serum-free medium.
2. Estrogen Priming and Recipient Preparation: Female NOD-scid or athymic nude mice (5–7 weeks old) receive subcutaneous 17β-estradiol valerate (1 µg in 50 µL peanut oil, twice weekly) beginning 48 hours before cell inoculation. This hormonal priming is essential to establish the estrogen-rich microenvironment required for T-47D-luc engraftment and sustained proliferation.
3. Orthotopic Mammary Fat Pad Injection: Under general anesthesia, a small skin incision is made over the inguinal mammary fat pad. A suspension of 5 × 10⁶ T-47D-luc cells (in 30–50 µL total volume, mixed 1:1 with Matrigel) is carefully injected into the fat pad using a Hamilton syringe. The skin is closed with surgical clips, and mice recover under continuous observation.
4. Baseline Bioluminescence Imaging and Cohort Stratification: At 10–14 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Tumor-bearing mice are stratified by photon flux intensity into homogeneous treatment cohorts, ensuring balanced baseline signal distributions across all experimental arms.
5. Therapeutic Dosing and Serial Bioluminescence Monitoring: Test compounds are administered according to the predefined regimen. Bioluminescence imaging is performed at regular intervals (typically weekly) to quantify tumor growth dynamics, treatment-induced signal attenuation, and potential regrowth. Photon flux values are normalized to baseline and plotted as normalized total flux (NTF) over time. Body weights and general health are recorded concurrently.
6. Endpoint Collection and Ex Vivo Confirmation: Upon reaching study endpoints (tumor volume ~1,500 mm³, humane moribund criteria, or scheduled termination), mice are euthanized. Primary tumors are excised, weighed, and photographed. Ex vivo bioluminescence imaging of excised tumors and organs is performed to confirm metastatic dissemination and validate in vivo imaging accuracy.
7. Histopathological and Molecular Endpoint Analysis: Tumor tissues are fixed for H&E and immunohistochemistry (ER^α, PR, Ki-67, phospho-RB, cleaved caspase-3), or snap-frozen for Western blot, qPCR, and RNA-seq. Blood samples may be collected for pharmacokinetic profiling and circulating estradiol verification.
8. Data Integration and Reporting: All bioluminescence time-course data, tumor growth curves, body weight trajectories, histopathology scores, and molecular biomarker results are compiled into a comprehensive study report with statistical analysis. Normalized photon flux kinetics are correlated with caliper-derived tumor volumes and pharmacodynamic readouts to generate integrated mechanism-of-action insights.

Fig 2. T-47D-luc Orthotopic Mouse Model construction workflow.

Case Study-T-47D-luc Orthotopic Mouse Model Development

In a preclinical program investigating endocrine therapy resistance mechanisms, the T-47D-luc orthotopic model was employed to evaluate the efficacy of a novel oral selective estrogen receptor degrader (SERD) administered as monotherapy and in combination with a CDK4/6 inhibitor. Following orthotopic engraftment under standardized estrogen supplementation, baseline bioluminescence imaging was performed to stratify mice into homogeneous cohorts based on photon flux intensity. Treatment arms received escalating doses of the test SERD, the CDK4/6 inhibitor alone, the combination regimen, or vehicle control over an extended dosing period. Serial bioluminescence imaging revealed rapid signal attenuation in the combination cohort within the first two weeks of treatment, with sustained suppression maintained throughout the study duration, while the SERD monotherapy group exhibited initial response followed by gradual signal rebound suggestive of emerging resistance. Endpoint histopathological analysis demonstrated reduced Ki-67 proliferation indices, diminished phospho-RB staining, and increased apoptotic signaling in the combination-treated tumors, alongside marked ER^α receptor downregulation in the SERD-treated groups. These temporal imaging and endpoint data collectively illustrate the model's unique capacity to capture both acute treatment response and delayed resistance emergence, providing actionable insights for optimizing endocrine combination strategies in the preclinical space.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your T-47D-luc orthotopic breast cancer study provides access to a specialized platform that bridges hormone-dependent tumor biology with quantitative optical imaging. Our distinguishing capabilities include:

• Authenticated T-47D-luc cell banking with documented STR profiling, mycoplasma clearance, and passage-controlled expansion to preserve genetic stability, hormone receptor fidelity, and luciferase reporter integrity across cohorts.
• In-house IVIS bioluminescence imaging infrastructure enabling quantitative, non-invasive tumor tracking with normalized photon flux analysis, capturing growth kinetics, treatment response, and recurrence patterns in real time.
• Standardized 17β-estradiol supplementation protocols with validated hormone level monitoring and pellet replacement scheduling, ensuring consistent estrogen-dependent engraftment and reproducible tumor signal kinetics.
• Integrated steroid receptor and cell cycle profiling featuring validated IHC panels for ERα, PR, Ki-67, phospho-RB, and cleaved caspase-3, alongside molecular readouts for PI3K/AKT/mTOR pathway activation.
• Flexible combination study designs supporting sequential or concurrent administration of endocrine agents, CDK4/6 inhibitors, PI3K inhibitors, and emerging targeted therapies, with imaging schedules synchronized to dosing regimens.
• Dedicated project scientists providing weekly bioluminescence data updates, interim response assessments, and collaborative interpretation of temporal pharmacodynamic trends to align preclinical outcomes with your clinical development roadmap.

Contact Us

If your preclinical program demands a hormone-dependent luminal A breast cancer model with the added power of real-time bioluminescence tracking, we invite you to reach out to us to explore how Alfa Cytology can design and execute a tailored T-47D-luc orthotopic study that captures the full temporal dynamics of tumor response and resistance. From protocol consultation and estrogen optimization through serial imaging and comprehensive endpoint analysis, our scientific team is committed to delivering quantitative, mechanism-informed insights that de-risk your endocrine therapy development pipeline. Contact us today to initiate your project and leverage our integrated bioluminescence imaging platform for your next-generation breast cancer drug candidate.

For research use only. Not intended for any clinical use.